Patents by Inventor Edoardo Mariani
Edoardo Mariani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220348545Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: May 6, 2022Publication date: November 3, 2022Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
-
Patent number: 11352327Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: July 21, 2020Date of Patent: June 7, 2022Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Publication number: 20210040040Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: July 21, 2020Publication date: February 11, 2021Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 10759761Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: April 23, 2019Date of Patent: September 1, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Publication number: 20190345108Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: April 23, 2019Publication date: November 14, 2019Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 10323003Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: November 3, 2017Date of Patent: June 18, 2019Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Publication number: 20180118686Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: November 3, 2017Publication date: May 3, 2018Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
-
Patent number: 9890122Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: July 22, 2016Date of Patent: February 13, 2018Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Publication number: 20160326117Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: July 22, 2016Publication date: November 10, 2016Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 9434691Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: October 17, 2014Date of Patent: September 6, 2016Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 9422326Abstract: There is described a process for the industrial synthesis of 11-methylene-18-methyl-estr-4-en-3,17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel.Type: GrantFiled: September 3, 2013Date of Patent: August 23, 2016Assignee: INDUSTRIALE CHIMICA S.r.l.Inventors: Roberto Lenna, Edoardo Mariani, Andrea Vanossi
-
Publication number: 20150239925Abstract: There is described a process for the industrial synthesis of 11-methylene-18-methyl-estr-4-en-3,17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of the progestin compounds Desogestrel and Etonogestrel.Type: ApplicationFiled: September 3, 2013Publication date: August 27, 2015Inventors: Roberto Lenna, Edoardo Mariani, Andrea Vanossi
-
Publication number: 20150111931Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
-
Patent number: 8841283Abstract: The invention relates to a process for the preparation of Drospirenone in high yields and purity starting from a compound of formula 2 wherein R is a hydroxyl protective group as defined in the claims, through a sequence of oxidation, deprotection, lactonization and water elimination steps, and wherein the steps of oxidation and lactonization are performed with 1,3,5-trichloro1,3,5-triazine-2,4,6-(1H,3H,5H)-trione (trichloroisocyanuric acid, TCCA) or 1,3-dichloro-1,3,5-triazine-2,4,6-(1H,3H,5H)-trione (dichloroisocyanuric acid, DCCA) or an alkaline metal salt thereof such as the sodium salt dihydrate (DCCA sodium salt) or 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (IBX). New synthetic intermediates useful for the synthesis of Drospirenone are disclosed, too.Type: GrantFiled: July 22, 2011Date of Patent: September 23, 2014Assignee: Newchem S.p.A.Inventors: Mauro Montorsi, Edoardo Mariani, Luca Gambarin, Gianmauro Orru′, Romeo Scalaprice, Massimo Merlo, Erika Andriolo
-
Publication number: 20130131335Abstract: The invention relates to a process for the preparation of Drospirenone in high yields and purity starting from a compound of formula 2 wherein R is a hydroxyl protective group as defined in the claims, through a sequence of oxidation, deprotection, lactonization and water elimination steps, and wherein the steps of oxidation and lactonization are performed with 1,3,5-trichloro1,3,5-triazine-2,4,6-(1H,3H,5H)-trione (trichloroisocyanuric acid, TCCA) or 1,3-dichloro-1,3,5-triazine-2,4,6-(1H,3H,5H)-trione (dichloroisocyanuric acid, DCCA) or an alkaline metal salt thereof such as the sodium salt dihydrate (DCCA sodium salt) or 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (IBX). New synthetic intermediates useful for the synthesis of Drospirenone are disclosed, too.Type: ApplicationFiled: July 22, 2011Publication date: May 23, 2013Applicant: NEWCHEM S.P.A.Inventors: Mauro Montorsi, Edoardo Mariani, Luca Gambarin, Gianmauro Orru, Romeo Scalaprice, Massimo Merlo, Erika Andriolo
-
Patent number: 8383809Abstract: A process for the preparation of Drospirenone (I) according to the scheme (A) wherein the substituent R is defined in the description. The process improves the product yield and purity by reducing the formation of undesired side-products and is particularly convenient for industrial-scale manufacturing.Type: GrantFiled: July 21, 2008Date of Patent: February 26, 2013Assignee: Newchem S.p.A.Inventors: Erika Andriolo, Mauro Montorsi, Stefano Rancan, Edoardo Mariani, Marco Bandini, Michele Contento, Achille Umani-Ronchi
-
Publication number: 20100222571Abstract: A process for the preparation of Drospirenone (I) according to the scheme (A) wherein the substituent R is defined in the description. The process improves the product yield and purity by reducing the formation of undesired side-products and is particularly convenient for industrial-scale manufacturing.Type: ApplicationFiled: July 21, 2008Publication date: September 2, 2010Applicant: NEWCHEM S.P.A.Inventors: Erika Andriolo, Mauro Montorsi, Stefano Rancan, Edoardo Mariani, Marco Bandini, Michele Contento, Achille Umani-Ronchi